Safiglipron
Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity
Shandong Suncadia Medicine Co · Phase 3 · Recruiting · Enrollment 648
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Treatment group A: HRS-7535 | n/r | n/r | n/r | n/r |
| Treatment group B: Placebo | n/r | n/r | n/r | n/r |
Not shown
- Treatment group A: HRS-7535: endpoint not reported
- Treatment group B: Placebo: endpoint not reported